● Recruiting

Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

Condition: Adult Patients With Adverse Risk Acute Myeloblastic Leukemia · Sponsor: Nantes University Hospital

PhasePhase 1

Planned participants12

Who can joinAll sexes, 60 Years to no upper limit

Healthy volunteersNo

About this study

To search for a Maximum Tolerated Dose (MTD) for the combination of daratumumab and induction chemotherapy with Idarubicin and cytarabine or CPX-351 in patients with Acute Myeloblastic Leukemia (AML) of poor prognosis

This description comes directly from the study's public registry record.

Talk to the study team

PIERRE PETERLIN · 02 40 08 32 71 · Pierre.PETERLIN@chu-nantes.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHU de Nantes

Nantes, France

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05749276